Login

Switch On Your HIV Smarts.

PrEP scales up, HIV incidence declines

PrEP scales up, HIV incidence declines

, by Liz Highleyman

We’re starting to see the effects of PrEP on population-level measures of HIV incidence, but progress is uneven. Read More

An HIV study: Starting for the money, staying for the questions

An HIV study: Starting for the money, staying for the questions

, by Cirrus Wood

Cirrus embarks on a two-year HIV prevention study, along the way mulling over what might be learned—and how his participation makes a difference. Read More

We asked clinicians: Would you prescribe doxycycline to someone for STI prevention?

We asked clinicians: Would you prescribe doxycycline to someone for STI prevention?

, by Emily Land

Overall, clinicians recognize the potential benefits of STI prophylaxis, but there’s still uncertainty over whether the protection offered is enough to justify risk of drug resistance, pill fatigue, and other concerns. Read More

PrEP use since 2012 is up, but uptake falls short of need

PrEP use since 2012 is up, but uptake falls short of need

, by Liz Highleyman

1.45 million Americans may be at substantial risk for HIV infection, but only 8% are taking PrEP. Women, people of color, and southern regions are underrepresented. Read More

CROI 2018: A roundup of the most exciting PrEP news & research

CROI 2018: A roundup of the most exciting PrEP news & research

, by Liz Highleyman

Liz Highleyman summarizes the PrEP and HIV prevention research presented recently at the domestic HIV conference, CROI, including a new possible PrEP drug, real world PrEP effectiveness, and more. Read More